PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 30, 2026British Journal of Clinical Pharmacology2 citationsOpen Access

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

View Full Paper
APAishwarya PrasadAAAnshu AroraAAArun Arora

Key Points

  • To compare the safety and efficacy of GLP-1 receptor agonists and non-GLP-1 agents for weight management in type 2 diabetes.
  • Used FDA medical and statistical reports for analysis.
  • Compared GLP-1 receptor agonists, GLP-1/GIP dual agonists, and non-GLP-1 agents.
  • Analyzed safety in 34,280 subjects and efficacy in 36,312 subjects.
  • Tirzepatide and liraglutide showed the greatest weight reductions.
  • Efficacy outcomes were generally favorable.
  • Safety signals were limited due to small sample sizes.

Abstract

Using FDA regulatory data, we compared GLP-1 RAs, GLP-1/GIP dual agonists and non-GLP-1 weight loss agents, finding the greatest weight reductions with tirzepatide and liraglutide. While efficacy outcomes were favourable, safety signals were limited by small sample sizes. Expanded real-world evidence is needed to better characterize long-term safety.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Prasad et al. (2026) studied this question.

synapsesocial.com/papers/69c9c5c5f8fdd13afe0bdb6chttps://doi.org/10.1002/bcp.70515
Ask AI
Helpful
Bookmark
Share
View Full Paper